Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy of Ertugliflozin on Reduction of Mitral Regurgitation in Patients With Functional Mitral Regurgitation Secondary to Left Ventricular Dysfunction

NCT04231331 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT04231331
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04231331 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy of Ertugliflozin on Reduction of Mitral Regurgitation in Patients With Functional Mitral Regurgitation Secondary to Left Ventricular Dysfunction
Lead sponsor
Asan Medical Center
Phase
Phase 3
Overall status
Completed
Start date
November 4, 2020
Completion date
November 15, 2023
Enrollment
128 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

left ventricular systolic dysfunction, mitral valve insufficiency